The antiinflammatory properties in the ACS setting were also confirmed by Deftereos et al. [48], showing that in patients with STEMI, the administration of colchicine after diagnostic angiography with a loading dose of 2 mg (1.5 mg + 0.5 mg after one hour) followed by 0.5 mg twice daily for 5 days, markedly suppressed levels of biomarkers reflecting post–MI inflammatory response, in particular neutrophil count and C-reactive protein (CRP) that were associated with infarct size, which, in turn, is directly related to prognosis [59]. The gene discussed is CRP; the disease is myocardial infarction.